Insulin Affecting Patents (Class 514/6.7)
-
Publication number: 20140171361Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.Type: ApplicationFiled: February 19, 2014Publication date: June 19, 2014Applicant: Salk Institute for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jaemyoung Suh
-
Patent number: 8735349Abstract: The present invention refers to a pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.Type: GrantFiled: May 9, 2012Date of Patent: May 27, 2014Assignee: Sanofi-Aventis Deutschland GmbHInventors: Louise Silvestre, Gabor Boka, Patrick Miossec
-
Publication number: 20140142035Abstract: The present invention provides a combination of compounds capable of modulating xenin activity and, insulin secretion and weight gain. The invention also provides methods for modulating GIP activity and insulin secretion in a subject, by modulating xenin activity in the subject.Type: ApplicationFiled: October 28, 2013Publication date: May 22, 2014Inventors: Burton M. Wice, Kenneth S. Polonsky
-
Publication number: 20140128320Abstract: The present invention relates to methods and compositions for treating and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway involving gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not limited to, metabolic syndrome, glucose intolerance, diabetes types 1 and 2, atherosclerosis and obesity.Type: ApplicationFiled: September 19, 2013Publication date: May 8, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Gerard KARSENTY, Patricia F. DUCY
-
Patent number: 8716221Abstract: The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.Type: GrantFiled: December 22, 2011Date of Patent: May 6, 2014Assignee: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.Inventors: Aifeng Lv, Changan Sun, Yali Wang
-
Publication number: 20140121154Abstract: This invention relates to novel compositions comprising analogs of glucagon, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways, including diabetes and other metabolic disorders. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.Type: ApplicationFiled: April 5, 2012Publication date: May 1, 2014Applicant: Longevity Biotech, Inc.Inventors: Scott Shandler, Samuel H. Gellman
-
Publication number: 20140107020Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 12, 2013Publication date: April 17, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
-
Publication number: 20140107026Abstract: The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subjectType: ApplicationFiled: October 28, 2013Publication date: April 17, 2014Inventors: Yu-Hua Tseng, C. Ronald Kahn
-
Publication number: 20140107025Abstract: An ocular drug delivery system including a composition in which a formulation having an active agent such as rHGH and or an rHGH mimic, e.g., that increases insulin growth factor (IGF) or that alters insulin growth factor binding protein (IGFBP) in a subject is dispersed in a pharmaceutical carrier. The composition is configured for placement in, around or on an eye of the subject, and the composition provides controlled release of an amount of the active agent to the eye effective to promote ocular surface and corneal neural regeneration and wound healing.Type: ApplicationFiled: March 15, 2013Publication date: April 17, 2014Inventor: Jade Therapeutics, LLC
-
Publication number: 20140107021Abstract: Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Method of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.Type: ApplicationFiled: September 13, 2013Publication date: April 17, 2014Applicant: Indiana University Research and Technology CorporationInventors: Richard D. DiMARCHI, Tao MA
-
Publication number: 20140105896Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 12, 2013Publication date: April 17, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
-
Publication number: 20140073563Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: September 6, 2013Publication date: March 13, 2014Applicant: SANOFIInventors: Oliver BOSCHEINEN, Matthias DREYER, Paul HABERMANN, Hans-Ludwig SCHAEFER, Mark SOMMERFELD, Thomas LANGER
-
Publication number: 20140051630Abstract: A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed. Isolation of a nucleic acid encoding a periostin isoform, panc, is also taught.Type: ApplicationFiled: January 28, 2013Publication date: February 20, 2014Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: Michael RUDNICKI, Johnathan SMID
-
Patent number: 8653026Abstract: Methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY-720 or an analog are described.Type: GrantFiled: December 20, 2012Date of Patent: February 18, 2014Inventor: Zhonigman Ma
-
Publication number: 20140038890Abstract: Methods of detecting a first species' Ig-CTF in a biological sample comprising exposing the biological sample to a first antibody of a second species that preferentially binds the first species' Ig-CTF or an antigen binding fragment of the antibody, forming a mixture, exposing the mixture to a second antibody or antigen-binding fragment of a third species that preferentially binds the first species' Ig, and detecting the Ig-CTF in the biological sample.Type: ApplicationFiled: February 22, 2012Publication date: February 6, 2014Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventor: Michael Pugia
-
Patent number: 8637459Abstract: Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-?1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation.Type: GrantFiled: November 7, 2007Date of Patent: January 28, 2014Assignee: Emory UniversityInventor: Shanthi Srinivasan
-
Patent number: 8623817Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: GrantFiled: January 17, 2012Date of Patent: January 7, 2014Assignee: Mannkind CorporationInventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
-
Publication number: 20140004175Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.Type: ApplicationFiled: June 18, 2013Publication date: January 2, 2014Applicant: Compugen Ltd.Inventors: Yossef KLIGER, Itamar Borukhov, Ofer Levy, Zohar Tiran, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Amir Toporik
-
Publication number: 20140005098Abstract: The present invention provides polypeptide derivatives of IGFBP-3 that are resistant to proteolytic cleavage. These IGFBP-3 derivatives are useful in a variety of therapeutic and diagnostic applications. Also provided are pharmaceutical compositions and kits comprising such IGFBP-3 derivatives and methods for using these derivatives for the treatment of a variety of disorders.Type: ApplicationFiled: February 24, 2012Publication date: January 2, 2014Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Jean-François Godeau, Yves Le Bouc
-
Patent number: 8609612Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.Type: GrantFiled: February 7, 2011Date of Patent: December 17, 2013Assignee: NGM Biopharmaceuticals, Inc.Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan
-
Patent number: 8592370Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.Type: GrantFiled: November 13, 2009Date of Patent: November 26, 2013Assignee: Poxel S.A.S.Inventors: Didier Mesangeau, Daniel Cravo, Annick Audet
-
Patent number: 8586036Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.Type: GrantFiled: April 9, 2010Date of Patent: November 19, 2013Assignee: XOMA Technology Ltd.Inventors: Alan M. Solinger, Patrick J. Scannon, Robert J. Bauer
-
Patent number: 8575096Abstract: The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.Type: GrantFiled: August 12, 2008Date of Patent: November 5, 2013Assignee: Novo Nordisk A/SInventors: Helle Birk Olsen, Thomas Børglum Kjeldsen, Per Balschmidt, Tine Glendorf, Svend Havelund
-
Patent number: 8575307Abstract: The present invention provides peptides and peptide analogs capable of inhibiting the activity of protein kinase C. The invention discloses use of such peptides and analogs for preparation of pharmaceutical compositions and methods for prevention, delay, suppression or treatment of type 2 diabetes using such compositions.Type: GrantFiled: June 28, 2006Date of Patent: November 5, 2013Assignee: Hadasit Medical Research Services & Development Ltd.Inventors: Eleazar Shafrir, Ehud Ziv, Hadas Reuveni, Masha Niv
-
Publication number: 20130288959Abstract: It is an object of the present invention to provide a newly identified insulin secretion regulation factor that can control blood sugar in the normal range, and a method for screening an antidiabetic drug using said factor. In accordance with the present invention, there is provided a composition which is (i) a protein comprising an amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4; or (ii) a protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in an amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4 and negatively regulating insulin secretion, as well as a method for screening antidiabetic drug using said protein or a nucleic acid encoding the same.Type: ApplicationFiled: September 2, 2011Publication date: October 31, 2013Applicant: TOKYO INSTITUTE OF TECHNOLOGYInventors: Takeshi Imai, Hiroshi Handa
-
Publication number: 20130281367Abstract: An agent for suppressing elevation of blood GIP level, an agent for suppressing elevation of blood insulin level, an agent for lowering blood triglyceride level after meal ingestion and an agent for suppressing elevation of blood glucose level, these agents containing potassium polyglutamates as active ingredients.Type: ApplicationFiled: December 20, 2011Publication date: October 24, 2013Applicant: KAO CORPORATIONInventors: Kotomi Ishimaru, Kazuhisa Sawada, Noriko Osaki
-
Patent number: 8551944Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.Type: GrantFiled: April 15, 2011Date of Patent: October 8, 2013Assignee: NGM Biopharmaceuticals, Inc.Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan, Peng Zhang
-
Patent number: 8541367Abstract: The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.Type: GrantFiled: March 12, 2010Date of Patent: September 24, 2013Assignee: Landing Biotech, Inc.Inventor: Jian-ning Liu
-
Publication number: 20130244932Abstract: Provided herein are methods for increasing insulin secretion from beta cells. Also provide herein are methods comprising administering to a subject in need of increased insulin secretion a composition comprising a compound that directly or indirectly activates adenylate cyclase and an E prostanoid 3 (EP3) receptor antagonist that attenuates G alpha-i-subfamily (GSIS)-mediated adenylate cyclase inhibition.Type: ApplicationFiled: February 22, 2013Publication date: September 19, 2013Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Mark Keller, Alan Attie, Michelle Kimple
-
Publication number: 20130244933Abstract: The present invention relates to a (poly)peptide or a peptidomimetic thereof having the biological activity of Conkunitzin-S1, wherein said (poly)peptide is selected from (a) a polypeptide comprising or having the amino acid sequence of SEQ ID NO: 1; (b) a polypeptide having at least 85% sequence identity to SEQ ID NO:1; or (c) a fragment of a) or b); wherein said (poly)peptide or peptidomimetic specifically modulates the activity of a channel having the activity of a Kv1.7 containing channel, for the treatment or prevention of metabolic diseases or conditions, or secondary diseases or conditions related to said metabolic diseases or conditions.Type: ApplicationFiled: April 8, 2013Publication date: September 19, 2013Applicants: Universitat zu Lubeck, Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Heinrich Terlau, Rocio Finol-Urdaneta, Stefan Becker, Walter Raasch
-
Publication number: 20130237473Abstract: The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.Type: ApplicationFiled: May 3, 2013Publication date: September 12, 2013Applicant: AstraZeneca ABInventors: John H. Dodd, Yi-Qun Shi, Wei Yang
-
Patent number: 8524661Abstract: Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment.Type: GrantFiled: July 11, 2011Date of Patent: September 3, 2013Assignee: Joslin Diabetes Center, Inc.Inventors: Mary Elizabeth Patti, Wanzhu Jin, Allison B. Goldine
-
Publication number: 20130225489Abstract: The present invention relates to methods of administering hypoglycemic agents and/or GLP-1 agonists.Type: ApplicationFiled: May 4, 2012Publication date: August 29, 2013Inventors: Mark A. Bush, Mary Colleen O'Neill
-
Publication number: 20130225488Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.Type: ApplicationFiled: September 28, 2007Publication date: August 29, 2013Inventors: Rajesh H. Bahekar, Braj Bhushan Lohray, Vidya Bhushan Lohray, Mukul R. Jain, Kaushik M. Banerjee, Pankaj Ramanbhai Patel
-
Publication number: 20130210713Abstract: The invention is directed to a method for preparing a collagen powder and to collagen powder that can be used for the preparation of a satiety inducing food product. The collagen powder of the invention is suitable as a food additive in food products for the reduction of hunger and as a possible treatment of obesity and its pathophysiological consequences, such as metabolic syndrome.Type: ApplicationFiled: May 30, 2011Publication date: August 15, 2013Applicant: HFP INGREDIËNTS B.V.Inventors: Jan Gert Ten Kate, Petrus Rimke Visser
-
Publication number: 20130203659Abstract: GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.Type: ApplicationFiled: October 15, 2012Publication date: August 8, 2013Inventors: Leslie P. MIRANDA, Katherine Ann WINTERS, Murielle VENIANT-ELLISON
-
Publication number: 20130195807Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.Type: ApplicationFiled: June 3, 2011Publication date: August 1, 2013Inventors: Andrew V. Schally, Barbara Ludwig, Stefan Bornstein, Norman L. Block
-
Publication number: 20130190230Abstract: A method of treating or preventing cognitive impairment deficits in subjects with age-associated cognitive decline or a dementing illness includes administering to the subject a therapeutically effective amount of amylin, an amylin agonist, or an amylin derivative to treat the cognitive impairment or deficit.Type: ApplicationFiled: July 30, 2012Publication date: July 25, 2013Applicant: Case Western Reserve UniversityInventors: Gemma Casadesus Smith, Brittany Adler, Mark Yarchoan
-
Publication number: 20130184203Abstract: The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4.Type: ApplicationFiled: July 27, 2011Publication date: July 18, 2013Applicants: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Josue Alfaro-Lopez, Abhinandini Sharma, Christopher J. Soares, Eugene Coats, Soumitra S. Ghosh
-
Patent number: 8481485Abstract: Full potency analogs of insulin are provided wherein the analog comprises a modification of the tyrosine residue at position 19 of the A chain.Type: GrantFiled: December 18, 2009Date of Patent: July 9, 2013Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, Jie Han
-
Patent number: 8476230Abstract: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and an immunoglobulin Fc region, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.Type: GrantFiled: January 4, 2008Date of Patent: July 2, 2013Assignee: Hanmi Science Co., LtdInventors: Dae Hae Song, Chang Ki Lim, Tae Hun Song, Young Hoon Kim, Se Chang Kwon, Gwan Sun Lee, Sung Youb Jung, In Young Choi
-
Publication number: 20130157929Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.Type: ApplicationFiled: June 24, 2011Publication date: June 20, 2013Applicant: ZEALAND PHARMA A/SInventors: Ditte Riber, Eddi Meier
-
Publication number: 20130157936Abstract: A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin.Type: ApplicationFiled: December 14, 2012Publication date: June 20, 2013Applicant: ALIZÉ PHARMA SASInventor: Alizé Pharma Sas
-
Patent number: 8460659Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.Type: GrantFiled: September 12, 2011Date of Patent: June 11, 2013Assignee: Janssen Biotech, Inc.Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Vedrana Stojanovic-Susulic, Raymond Sweet, Fang Teng, Alexey Teplyakov, Linda Wu, Sheng-Jiun Wu
-
Publication number: 20130143793Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.Type: ApplicationFiled: April 27, 2011Publication date: June 6, 2013Applicant: ZEALAND PHARMA A/SInventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted
-
Publication number: 20130136738Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.Type: ApplicationFiled: January 21, 2011Publication date: May 30, 2013Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan
-
Publication number: 20130130976Abstract: An insulin degrading enzyme (IDE) inhibitor for use in the treatment of a disease selected from the group consisting of an autoimmune disease of the central nervous system and a neurodegenerative disease is disclosed.Type: ApplicationFiled: August 4, 2011Publication date: May 23, 2013Inventors: Dan Frenkel, Hilit Levy, Nofit Borenstein, Dorit Farfara, Dorit Trudler
-
Publication number: 20130130975Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.Type: ApplicationFiled: April 15, 2011Publication date: May 23, 2013Applicant: NGM Biopharmaceuticals, Inc.Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan, Peng Zhang
-
Publication number: 20130123172Abstract: The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.Type: ApplicationFiled: December 20, 2012Publication date: May 16, 2013Applicant: DIAPIN THERAPEUTICS LLCInventor: DIAPIN THERAPEUTICS LLC
-
Publication number: 20130109621Abstract: Methods and compositions are provided for stimulating insulin production, increasing beta cell mass, or decreasing beta cell loss in a subject. For example, methods of the embodiments can comprise administration of a corticotropin-releasing factor (CRF)1 receptor agonist and a CRF2 receptor agonist. Also provided are pharmaceutical compositions comprising a selective CRF1 receptor agonist and a selective CRF2 receptor agonist.Type: ApplicationFiled: October 24, 2012Publication date: May 2, 2013Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventor: Research Development Foundation